Visual summary: mechanisms mapped

Nodes: Gas6/PROS1 (ligands) connect to AXL/MERTK/TYRO3; downstream processes: efferocytosis (anti-inflammatory), platelet/coagulation links (hemostasis), fibroblast activation → fibrosis, EMT/immune evasion → NSCLC progression.

Strengths (what the paper does well)

• Comprehensive, up-to-date narrative (185 refs) integrating molecular mechanisms, preclinical models, and clinical biomarker observations Ban et al., 2025 — comprehensive reference base
• Explicit emphasis on context- and stage-dependence (e.g., AXL inhibition can worsen acute inflammation but improve fibrosis later), which is critical for translational planning.
• Brings together coagulation/platelet biology (Gas6/PROS1 links) with lung injury and COVID-19 — a useful, cross-discipline synthesis supported by several clinical biomarker papers.

Key limitations & blindspots (critical)

• Narrative (not systematic): selection and publication biases are possible; the review does not present a PRISMA-style search, risk-of-bias assessment or meta-analysis, limiting quantitative inference.
• Translational gaps: many mechanistic claims are driven by mouse or in vitro data (AXL/MERTK knockout or inhibitor models) that may not predict human outcomes; species differences in TAM signaling are known and noted as a blindspot.
• Stage/context dependence not resolved: the review points out contradictory effects (anti‑inflammatory vs pro‑fibrotic) but cannot resolve them with pooled evidence; therapeutic recommendations are therefore provisional.
• Data availability: no new data or re-analysis were presented; reproducibility score is low because the paper synthesizes others' data rather than reporting methods or datasets that can be re-run.

Evidence-weighted critique — selected representative citations

Representative mechanistic anchors cited by the review (selected, each with extract):

• Rothlin et al., 2015 — TAM immune homeostasis
• Wang et al., 2021 — AXL as SARS‑CoV‑2 receptor candidate
• Espindola et al., 2018 — TAM inhibition in IPF models
• Morse et al., 2019 — MERTK+ macrophages in IPF

Each of these anchor studies is cited by the review and supports specific mechanistic claims; however, they are heterogeneous in models, endpoints, and translational readiness.

Practical assessment & prioritized next steps (what the field needs)

1. Systematic evidence synthesis: produce a living systematic review + meta-analysis of TAM-targeting interventions (preclinical effect sizes by model and clinical biomarker cohorts) to quantify heterogeneity and stage-specific effects.
2. Human-focused mechanistic data: single-cell and spatial transcriptomics in acute vs chronic lung injury (including post‑COVID fibrosis) to map TAM receptor/ligand expression by cell type and disease stage.
3. Translational trials design: small adaptive trials testing TAM inhibitors in well‑phenotyped IPF or NSCLC cohorts with biomarker-guided enrollment (sAXL/Gas6 levels, MERTK+ macrophage signature) and pre-specified safety endpoints for coagulation/thrombosis given Gas6/PROS1 roles.
4. Functional target validation: conditional cell-type specific knockouts (endothelial vs macrophage vs fibroblast) in fibrotic and infection models to resolve cell-specific roles and avoid systemic on-target adverse effects (e.g., thrombosis).

Interactive: run an AI Scientist to evolve analysis

If you want iterative analyses (extract raw data from cited full texts, re-calculate effect sizes, map co-citation networks, or design experiments), launch the agent below.

Author review quick-links

Open bespoke BGPT Author reviews: